Harvard Bioscience (HBIO)
Market Price (6/23/2026): $6.11 | Market Cap: $27.3 MilSector: Health Care | Industry: Health Care Equipment
Harvard Bioscience (HBIO)
Market Price (6/23/2026): $6.11Market Cap: $27.3 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Biopharmaceutical R&D, Gene Editing & Therapy, Show more. | Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -160% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 137% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -6.4%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -9.2%, Rev Chg QQuarterly Revenue Change % is -4.7% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -40% Key risksHBIO key risks include [1] substantial doubt about its ability to continue as a going concern due to a critical need to refinance significant debt and [2] potential delisting from the Nasdaq exchange. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Biopharmaceutical R&D, Gene Editing & Therapy, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -160% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 137% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -6.4%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -9.2%, Rev Chg QQuarterly Revenue Change % is -4.7% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -40% |
| Key risksHBIO key risks include [1] substantial doubt about its ability to continue as a going concern due to a critical need to refinance significant debt and [2] potential delisting from the Nasdaq exchange. |
Qualitative Assessment
AI Analysis | Feedback
Harvard Bioscience (HBIO) stock has remained largely at the same level since 2/28/2026 because of the following key factors:
1. Mixed Fiscal Q1 2026 Financial Results Provided Offset Signals to Investors.
Harvard Bioscience reported a narrower net loss of $(3.4) million in fiscal Q1 2026, a significant improvement from $(50.3) million in fiscal Q1 2025 (which included a $48.0 million goodwill impairment). The company also improved its adjusted gross margin to 59% in fiscal Q1 2026 from 56% in the prior year, driven by a shift towards higher-margin products. However, these positive indicators were balanced by a 4.6% year-over-year decline in revenue, which reached $20.8 million and missed analyst forecasts. Adjusted EBITDA remained flat at $0.8 million. This mixed financial performance, showcasing both operational improvements and top-line challenges, likely contributed to the stock maintaining a relatively stable, post-split price level as investors weighed the various factors.
2. 10-for-1 Reverse Stock Split Reset the Per-Share Price for Stability.
A 10-for-1 reverse stock split became effective on March 13, 2026. This corporate action dramatically increased the nominal per-share price of HBIO stock. While it did not fundamentally alter the company's overall market capitalization, it established a new, higher trading range (approximately $5-$7 per share) within which the stock has largely consolidated since. This recalibration of the share price created a new baseline level around which subsequent trading activity occurred, influencing the perception of stability for the period under review.
Show more
Harvard Bioscience (HBIO) stock has remained largely at the same level since 2/28/2026 because of the following key factors:
1. Mixed Fiscal Q1 2026 Financial Results Provided Offset Signals to Investors.
Harvard Bioscience reported a narrower net loss of $(3.4) million in fiscal Q1 2026, a significant improvement from $(50.3) million in fiscal Q1 2025 (which included a $48.0 million goodwill impairment). The company also improved its adjusted gross margin to 59% in fiscal Q1 2026 from 56% in the prior year, driven by a shift towards higher-margin products. However, these positive indicators were balanced by a 4.6% year-over-year decline in revenue, which reached $20.8 million and missed analyst forecasts. Adjusted EBITDA remained flat at $0.8 million. This mixed financial performance, showcasing both operational improvements and top-line challenges, likely contributed to the stock maintaining a relatively stable, post-split price level as investors weighed the various factors.
2. 10-for-1 Reverse Stock Split Reset the Per-Share Price for Stability.
A 10-for-1 reverse stock split became effective on March 13, 2026. This corporate action dramatically increased the nominal per-share price of HBIO stock. While it did not fundamentally alter the company's overall market capitalization, it established a new, higher trading range (approximately $5-$7 per share) within which the stock has largely consolidated since. This recalibration of the share price created a new baseline level around which subsequent trading activity occurred, influencing the perception of stability for the period under review.
3. Analyst Consensus and Price Target Anchored Stock Valuation.
Multiple analysts have maintained a "Buy" or "Outperform" consensus rating for Harvard Bioscience during this period, with a consistent average price target hovering around $6.00 to $6.12 per share. This relatively tight range in analyst expectations, closely aligning with the stock's post-split trading activity, suggests that the market has largely absorbed available information and converged on a valuation point. The absence of significant deviations in price targets implies a lack of new, compelling catalysts to drive the stock substantially above or below this established level.
4. Strategic Initiatives and Long-Term Guidance Offer Future, Not Immediate, Impact.
Harvard Bioscience continued to implement strategic initiatives, including the consolidation of manufacturing operations and "Project Viking," which are designed to enhance efficiency and achieve future cost savings. The company also reaffirmed its full-year 2026 financial guidance, projecting mid-single-digit revenue growth in fiscal Q2 2026 and anticipating a revenue ramp in the second half of 2026 driven by new product innovation. While these initiatives and forward-looking statements provide a positive long-term outlook, their tangible impact on financial results within the analysis period (since February 28, 2026) was not sufficient to generate significant stock price appreciation, contributing to a holding pattern as investors await concrete outcomes.
Show less
Stock Movement Drivers
Fundamental Drivers
The -1.3% change in HBIO stock from 2/28/2026 to 6/22/2026 was primarily driven by a -2.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282026 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.14 | 6.05 | -1.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 87 | 86 | -2.1% |
| P/S Multiple | 0.3 | 0.3 | 1.2% |
| Shares Outstanding (Mil) | 4 | 4 | -0.4% |
| Cumulative Contribution | -1.3% |
Market Drivers
2/28/2026 to 6/22/2026| Return | Correlation | |
|---|---|---|
| HBIO | -1.3% | |
| Market (SPY) | 8.8% | 32.6% |
| Sector (XLV) | -5.9% | 4.6% |
Fundamental Drivers
The -20.4% change in HBIO stock from 11/30/2025 to 6/22/2026 was primarily driven by a -18.4% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.61 | 6.05 | -20.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 87 | 86 | -2.1% |
| P/S Multiple | 0.4 | 0.3 | -18.4% |
| Shares Outstanding (Mil) | 4 | 4 | -0.4% |
| Cumulative Contribution | -20.4% |
Market Drivers
11/30/2025 to 6/22/2026| Return | Correlation | |
|---|---|---|
| HBIO | -20.4% | |
| Market (SPY) | 9.5% | 27.3% |
| Sector (XLV) | -4.0% | 3.0% |
Fundamental Drivers
The 29.7% change in HBIO stock from 5/31/2025 to 6/22/2026 was primarily driven by a 40.5% change in the company's P/S Multiple.| (LTM values as of) | 5312025 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.67 | 6.05 | 29.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 91 | 86 | -6.4% |
| P/S Multiple | 0.2 | 0.3 | 40.5% |
| Shares Outstanding (Mil) | 4 | 4 | -1.4% |
| Cumulative Contribution | 29.7% |
Market Drivers
5/31/2025 to 6/22/2026| Return | Correlation | |
|---|---|---|
| HBIO | 29.7% | |
| Market (SPY) | 27.7% | 20.2% |
| Sector (XLV) | 15.2% | 11.0% |
Fundamental Drivers
The -89.2% change in HBIO stock from 5/31/2023 to 6/22/2026 was primarily driven by a -84.6% change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 55.90 | 6.05 | -89.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 115 | 86 | -25.3% |
| P/S Multiple | 2.1 | 0.3 | -84.6% |
| Shares Outstanding (Mil) | 4 | 4 | -5.8% |
| Cumulative Contribution | -89.2% |
Market Drivers
5/31/2023 to 6/22/2026| Return | Correlation | |
|---|---|---|
| HBIO | -89.2% | |
| Market (SPY) | 85.1% | 25.2% |
| Sector (XLV) | 23.4% | 18.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HBIO Return | 64% | -61% | 93% | -61% | -68% | -12% | -86% |
| Peers Return | 42% | -19% | -8% | 2% | 2% | -12% | -4% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| HBIO Win Rate | 67% | 33% | 42% | 8% | 42% | 33% | |
| Peers Win Rate | 77% | 40% | 50% | 47% | 50% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| HBIO Max Drawdown | -25% | -70% | -35% | -63% | -87% | -38% | |
| Peers Max Drawdown | -17% | -33% | -34% | -21% | -35% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, A, BIO, DHR, WAT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/22/2026 (YTD)
How Low Can It Go
| Event | HBIO | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -17.4% | -9.5% |
| % Gain to Breakeven | 21.0% | 10.5% |
| Time to Breakeven | 115 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -22.0% | -6.7% |
| % Gain to Breakeven | 28.2% | 7.1% |
| Time to Breakeven | 16 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -46.4% | -33.7% |
| % Gain to Breakeven | 86.6% | 50.9% |
| Time to Breakeven | 26 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -39.4% | -19.2% |
| % Gain to Breakeven | 65.0% | 23.8% |
| Time to Breakeven | 780 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -17.9% | -3.7% |
| % Gain to Breakeven | 21.7% | 3.9% |
| Time to Breakeven | 62 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -46.4% | -12.2% |
| % Gain to Breakeven | 86.7% | 13.9% |
| Time to Breakeven | 702 days | 62 days |
In The Past
Harvard Bioscience's stock fell -3.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 3.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | HBIO | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -22.0% | -6.7% |
| % Gain to Breakeven | 28.2% | 7.1% |
| Time to Breakeven | 16 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -46.4% | -33.7% |
| % Gain to Breakeven | 86.6% | 50.9% |
| Time to Breakeven | 26 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -39.4% | -19.2% |
| % Gain to Breakeven | 65.0% | 23.8% |
| Time to Breakeven | 780 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -46.4% | -12.2% |
| % Gain to Breakeven | 86.7% | 13.9% |
| Time to Breakeven | 702 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -41.6% | -6.8% |
| % Gain to Breakeven | 71.2% | 7.3% |
| Time to Breakeven | 714 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -29.1% | -17.9% |
| % Gain to Breakeven | 41.1% | 21.8% |
| Time to Breakeven | 536 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -25.0% | -15.4% |
| % Gain to Breakeven | 33.3% | 18.2% |
| Time to Breakeven | 210 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -56.4% | -53.4% |
| % Gain to Breakeven | 129.2% | 114.4% |
| Time to Breakeven | 517 days | 1085 days |
In The Past
Harvard Bioscience's stock fell -3.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 3.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Harvard Bioscience (HBIO)
Harvard Bioscience (HBIO) develops, manufactures, and sells a wide array of scientific instruments and technologies critical for life sciences research. The company's primary focus is to enable fundamental research, discovery, and preclinical testing, which are essential stages in drug development across pharmaceutical and biotechnology sectors.
HBIO's product portfolio is diverse, encompassing both cellular and molecular technology instruments as well as precision scientific measuring equipment. Key offerings include various pumps like syringe and peristaltic pumps, instruments for tissue and organ-based lab research (e.g., surgical products, infusion systems, behavior research systems), and analytical tools such as spectrophotometers, microplate readers, and gel electrophoresis equipment. Furthermore, the company provides sophisticated data acquisition systems for cellular analysis, micro electrode array solutions for in vivo recordings, and a range of preclinical products, marketed under reputable brands like Harvard Apparatus, DSI, and Biochrom.
The company serves a broad international customer base within the scientific research community. Its products are utilized by research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories. HBIO also supplies contract research organizations (CROs), academic labs, and government researchers globally, providing them with the necessary tools for their experimental, analytical, and developmental endeavors.
AI Analysis | Feedback
Think of them as a smaller-scale Thermo Fisher Scientific or Danaher, providing the essential scientific instruments and lab equipment that researchers use for drug discovery and pre-clinical testing.
AI Analysis | Feedback
- Lab Research Instruments: A range of tools including syringe and peristaltic pumps, surgical products, infusion systems, and behavior research systems for tissue and organ-based lab research.
- Cellular and Molecular Analysis Instruments: Products such as spectrophotometers, microplate readers, amino acid analyzers, and gel electrophoresis equipment for fundamental research.
- Electroporation and Electrofusion Instruments: Specialized devices used to introduce substances into cells or fuse cells using electrical pulses.
- Precision Scientific Measuring Instrumentation: Equipment covering data acquisition systems with custom amplifier configurations, micro electrode array solutions, and vitro-systems for cellular recordings.
- Preclinical Testing Products: Technologies, products, and services specifically designed for early-stage drug development and testing.
AI Analysis | Feedback
Harvard Bioscience (HBIO) primarily sells its products and services to research scientists within various organizations and institutions rather than directly to individuals. The company's major customers fall into the following categories:
- Pharmaceutical and biotechnology companies
- Universities and academic laboratories
- Hospitals
- Government laboratories and researchers
- Contract research organizations (CROs)
The provided company description does not list specific names of customer companies, only the categories of organizations they serve.
```AI Analysis | Feedback
AI Analysis | Feedback
John Duke, President & Chief Executive Officer
John Duke was appointed President and Chief Executive Officer of Harvard Bioscience, as well as a member of its Board of Directors, in 2025. Previously, Mr. Duke served as the Chief Executive Officer of Plastic Molding Technology (PMT), where he achieved approximately 20% annual revenue growth during his tenure. Before joining PMT, he was the Executive Vice President and Chief Business Officer of Lyten, Inc., an advanced materials company. Mr. Duke also spent over 20 years at Corning Incorporated, holding various leadership positions including Corporate Vice President, Corporate Officer, VP & GM - Glass Microsystems, and Vice President, Business Operations - Corning Life Sciences.
Mark Frost, Chief Financial Officer & Treasurer
Mark Frost was appointed Chief Financial Officer and Treasurer of Harvard Bioscience, effective March 6, 2026, after serving as Interim CFO & Treasurer from April 10, 2025. He brings over 30 years of financial and executive-level management experience from both private and public companies. Prior to joining Harvard Bioscience, Mr. Frost served as the Chief Financial Officer of Fathom (NYSE:FATH), a digital manufacturing company, and before that, as CFO for Argon Medical Devices, a medical devices company that was planning to go public.
Nitya Shetty, Vice President, Global Research and Development
Nitya Shetty joined Harvard Bioscience in October 2021 as Vice President, Global Research and Development. Her background includes 15 years at Spacelabs Healthcare, where she specialized in Patient Monitoring, and seven years at GE Consumer & Industrial. Ms. Shetty has experience in developing innovative and high-performance R&D centers across multiple geographies that support revenue generation.
Ryan Wallace, Senior Vice President Global Sales, Preclinical Systems
Ryan Wallace was named Senior Vice President Global Sales, Preclinical Systems in April 2020. In this role, he is responsible for leading Harvard Bioscience's global direct sales efforts, with a focus on leading Clinical Research Organizations (CROs), pharmaceutical companies, and certain strategic accounts.
Diane Houston, Senior Director of Applications and Business Intelligence (Implied from search results as a key leader, actual title from company website not explicitly provided in snippets)
Diane Houston has extensive experience transforming sales analytics and fleet management, and has led numerous projects resulting in significant cost reductions. Before joining Harvard Bioscience, she held leadership roles in both private and public companies, including Kaz, Paychex, and Oracle, and spent half of her career as a consultant, leading small teams through significant systems changes for a wide range of businesses.
AI Analysis | Feedback
The most significant risk stems from the company's **financial health and high leverage**. Harvard Bioscience has been characterized by struggles for consistent profitability and efficient growth, with profit margins considerably thinner than the industry average. The company carries a notable debt load, which poses financial risk, especially in a volatile market environment. Its financial strength is rated as poor due to high leverage and liquidity concerns, and there has been a high probability of financial distress indicated by analytical models. While recent debt refinancing has occurred, the underlying issues of high leverage and operational costs relative to revenue continue to present a substantial challenge.
Another key risk is the **intense competitive landscape and limited organic growth potential**. Harvard Bioscience operates as a smaller provider in the vast life sciences tools and bioprocess market, which is dominated by larger entities with immense resources. This niche focus, while offering some insulation from direct competition, also caps the company's growth potential and limits its ability to achieve significant economies of scale. The company's revenue growth has been modest, sometimes stagnant, and heavily reliant on acquisitions rather than organic expansion. In 2025, the company experienced a decline in revenue, signaling weaker demand from distributors, contract research organizations (CROs), and academic institutions. Analysts forecast Harvard Bioscience's revenue to grow slower than the broader U.S. market.
Finally, Harvard Bioscience has faced risks associated with its **Nasdaq listing and share price volatility**, which can impact investor confidence and capital-raising abilities. The company previously received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, which could have led to delisting. Although the company received an extension and implemented a reverse stock split to regain compliance, the necessity of such actions highlights underlying concerns about its market valuation, liquidity, and ability to raise capital. Such events can also negatively affect employee morale, customer trust, and business development opportunities.
AI Analysis | Feedback
AI Analysis | Feedback
Harvard Bioscience (HBIO) operates within several addressable markets related to life sciences research and drug development. Below are the estimated market sizes for their main product and service categories:
- The global Scientific Instruments Market was valued at approximately USD 43.28 billion in 2024 and is projected to reach USD 66 billion by 2033, growing at a compound annual growth rate (CAGR) of 4.8% during the forecast period (2026–2033).
- The global Cell Analysis Instruments Market is expected to grow from USD 22.94 billion in 2025 to USD 34.49 billion by 2031, at a CAGR of 7.02% over 2026-2031.
- The global Preclinical Assets Market was valued at USD 5.87 billion in 2024 and is projected to grow to USD 9.3 billion by 2029, with a CAGR of 9.8%.
- The global Preclinical CRO Market is estimated at USD 8.20 billion in 2026 and is expected to reach USD 11.74 billion by 2031, growing at a CAGR of 7.45% during the forecast period (2026-2031). Another estimate indicates the market was USD 10.11 billion in 2025 and is projected to increase to USD 32.61 billion by 2034, demonstrating a CAGR of 13.90% between 2026-2034.
- The global Precision Measuring Tools Market was valued at USD 9.89 billion in 2025 and is expected to grow to USD 13.9 billion by 2030, at a CAGR of 7%.
- The global Biotechnology Instruments Market was valued at USD 61.1 billion in 2022 and is expected to grow at a CAGR of over 4.4% between 2023 and 2032, reaching USD 96.1 billion by 2032. Another report indicates the market size was USD 80.76 billion in 2024 and is expected to grow to USD 173.96 billion by 2033, at a CAGR of 8.9% during the forecast period (2025-2033).
- The global Cell Processing Instruments Market was valued at USD 6.39 billion in 2024 and is anticipated to grow from USD 6.82 billion in 2025 to USD 12.49 billion by 2034, exhibiting a CAGR of 7.0% during 2025–2034.
- The global Laboratory Equipment Market size is estimated at USD 35.90 billion in 2025 and is predicted to increase to approximately USD 74.22 billion by 2035, expanding at a CAGR of 7.53% between 2026 to 2035.
- The global Tissue Diagnostics Market is expected to grow from USD 6.45 billion in 2025 to USD 9.33 billion by 2031, reflecting a 6.35% CAGR (2026-2031). Another source projects a valuation of USD 10.86 billion by 2030, growing at a CAGR of 10.0% from 2025.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for Harvard Bioscience (HBIO) over the next 2-3 years:
- Expansion of New Product Innovation (NPI) and Focus on Translational Science: Harvard Bioscience anticipates revenue growth to be driven by new product innovation, particularly in the translational science market. This includes accelerating revenue from its NPI pipeline, which features offerings such as MeshMEA and organoid research platforms, as well as next-generation telemetry and bioproduction tools.
- Stabilized NIH Funding Environment: The company expects revenue growth to be supported by a stabilized funding environment from the National Institutes of Health (NIH), which historically impacts orders from academic and government research laboratories.
- Increasing Mix of Higher-Margin Recurring Revenue: Harvard Bioscience is strategically shifting towards higher-margin consumables, software, and services, aiming to increase the proportion of recurring revenue within its total sales.
- Operational Efficiencies and Cost Reductions: Initiatives such as the strategic consolidation of manufacturing operations, including the phased closure of the Holliston, Massachusetts facility, are expected to yield significant cost savings. These efficiencies can enhance financial flexibility and enable further investment in growth opportunities, indirectly contributing to revenue expansion.
AI Analysis | Feedback
Share Issuance
- Harvard Bioscience completed a 1-for-10 reverse stock split, approved on March 6, 2026, and effective March 13, 2026, to regain compliance with Nasdaq's minimum bid price requirement.
- This action reduced the number of outstanding common shares from approximately 44,719,894 to approximately 4,471,989.
Inbound Investments
- The company completed a comprehensive debt refinancing in December 2025, which extended its debt maturity to 2029.
- This refinancing is expected to reduce annual debt service by $3 million, generating annual cash savings.
- As of December 31, 2025, Harvard Bioscience had $40.0 million in outstanding borrowings under its Credit Agreement.
Capital Expenditures
- Harvard Bioscience launched "Project Viking" in January 2026, a strategic initiative to consolidate its manufacturing footprint.
- Project Viking is anticipated to generate approximately $3 million in cost savings in 2027 and $4 million annually from 2028 onwards, with estimated pre-tax restructuring charges of $3.4 million to $4.4 million.
- Cash used in investing activities for periods ending December 31, 2025, included amounts of $599,000, $466,000, $1,863,000, and $1,344,000.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Harvard Bioscience Earnings Notes | 12/16/2025 | |
| Harvard Bioscience Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 229.65 |
| Mkt Cap | 32.5 |
| Rev LTM | 5,501 |
| Op Inc LTM | 1,079 |
| FCF LTM | 722 |
| FCF 3Y Avg | 869 |
| CFO LTM | 981 |
| CFO 3Y Avg | 1,125 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.7% |
| Rev Chg 3Y Avg | 0.5% |
| Rev Chg Q | 4.9% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Inc Chg LTM | 1.7% |
| Op Inc Chg 3Y Avg | -10.2% |
| Op Mgn LTM | 17.1% |
| Op Mgn 3Y Avg | 19.0% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 19.0% |
| CFO/Rev 3Y Avg | 19.5% |
| FCF/Rev LTM | 14.4% |
| FCF/Rev 3Y Avg | 15.6% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Design, development, production and distribution of products and services that enable fundamental | 87 | 94 | 112 | ||
| Instruments, equipment, software and accessories | 108 | 114 | |||
| Service, maintenance and warranty contracts | 5 | 5 | |||
| Total | 87 | 94 | 112 | 113 | 119 |
| $ Mil | 2012 | 2011 | 2010 |
|---|---|---|---|
| LSRT | 14 | 14 | 17 |
| Unallocated | -4 | -5 | -6 |
| Other | -6 | -3 | -1 |
| Total | 3 | 6 | 10 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Design, development, production and distribution of products and services that enable fundamental | -57 | -12 | -3 |
| Total | -57 | -12 | -3 |
| $ Mil | 2012 | 2011 | 2010 |
|---|---|---|---|
| LSRT | 133 | 126 | 124 |
| Other | 0 | 0 | 0 |
| Unallocated | 0 | 0 | 0 |
| Total | 133 | 127 | 125 |
Price Behavior
| Market Price | $6.05 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/19/2001 | |
| Distance from 52W High | -23.1% | |
| 50 Days | 200 Days | |
| DMA Price | $6.06 | $5.71 |
| DMA Trend | up | up |
| Distance from DMA | -0.1% | 6.0% |
| 3M | 1YR | |
| Volatility | 95.9% | 97.1% |
| Downside Capture | 446.09 | 229.22 |
| Upside Capture | 298.22 | 183.20 |
| Correlation (SPY) | 36.5% | 21.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 5.70 | 4.61 | 2.68 | 2.05 | 1.79 | 1.94 |
| Up Beta | 7.06 | 2.94 | 2.43 | 2.68 | 2.21 | 2.11 |
| Down Beta | -2.58 | -2.76 | 0.26 | -0.86 | 0.21 | 1.72 |
| Up Capture | 409% | 569% | 356% | 292% | 350% | 163% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 12 | 26 | 33 | 58 | 114 | 323 |
| Down Capture | 1128% | 1025% | 348% | 254% | 176% | 113% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 8 | 15 | 29 | 65 | 135 | 401 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HBIO | |
|---|---|---|---|---|
| HBIO | 24.2% | 97.2% | 0.64 | - |
| Sector ETF (XLV) | 14.7% | 15.0% | 0.70 | 12.1% |
| Equity (SPY) | 26.1% | 12.4% | 1.59 | 21.4% |
| Gold (GLD) | 24.1% | 27.5% | 0.77 | 7.1% |
| Commodities (DBC) | 18.5% | 18.8% | 0.77 | -5.1% |
| Real Estate (VNQ) | 11.8% | 13.8% | 0.57 | 16.6% |
| Bitcoin (BTCUSD) | -40.2% | 42.5% | -1.09 | 3.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HBIO | |
|---|---|---|---|---|
| HBIO | -39.3% | 96.1% | -0.17 | - |
| Sector ETF (XLV) | 5.5% | 14.7% | 0.19 | 19.6% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 25.0% |
| Gold (GLD) | 17.1% | 18.3% | 0.76 | 6.1% |
| Commodities (DBC) | 7.5% | 19.4% | 0.28 | 2.9% |
| Real Estate (VNQ) | 2.1% | 18.9% | 0.01 | 20.5% |
| Bitcoin (BTCUSD) | 9.4% | 54.1% | 0.37 | 9.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HBIO | |
|---|---|---|---|---|
| HBIO | -16.1% | 79.8% | 0.09 | - |
| Sector ETF (XLV) | 9.5% | 16.6% | 0.46 | 19.7% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 24.6% |
| Gold (GLD) | 12.2% | 16.1% | 0.62 | 6.4% |
| Commodities (DBC) | 6.0% | 18.0% | 0.26 | 7.8% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 20.1% |
| Bitcoin (BTCUSD) | 59.9% | 66.8% | 1.00 | 7.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/15/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/12/2026 | -20.9% | -26.9% | -9.4% |
| 3/12/2026 | -2.6% | -3.8% | -15.0% |
| 11/6/2025 | -7.3% | 5.7% | 28.6% |
| 8/11/2025 | -9.2% | 0.2% | -17.1% |
| 5/12/2025 | 11.8% | 7.8% | 88.8% |
| 3/12/2025 | -10.1% | -11.6% | -39.8% |
| 11/7/2024 | -15.2% | -23.0% | -19.9% |
| 8/8/2024 | 11.8% | 0.7% | -2.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 15 | 13 |
| # Negative | 13 | 10 | 12 |
| Median Positive | 7.9% | 5.9% | 14.0% |
| Median Negative | -7.3% | -12.1% | -15.2% |
| Max Positive | 14.7% | 53.6% | 88.8% |
| Max Negative | -20.9% | -36.6% | -39.8% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/12/2026 | -20.9% | -26.9% | -9.4% |
| 3/12/2026 | -2.6% | -3.8% | -15.0% |
| 11/6/2025 | -7.3% | 5.7% | 28.6% |
| 8/11/2025 | -9.2% | 0.2% | -17.1% |
| 5/12/2025 | 11.8% | 7.8% | 88.8% |
| 3/12/2025 | -10.1% | -11.6% | -39.8% |
| 11/7/2024 | -15.2% | -23.0% | -19.9% |
| 8/8/2024 | 11.8% | 0.7% | -2.9% |
| 5/7/2024 | -4.3% | -13.5% | -21.7% |
| 3/7/2024 | 9.7% | 6.8% | 10.0% |
| 1/5/2024 | 2.5% | 0.8% | -3.7% |
| 11/7/2023 | -1.2% | -4.9% | 10.9% |
| 8/8/2023 | -2.0% | -11.5% | -5.3% |
| 4/25/2023 | 7.1% | 21.4% | 15.9% |
| 3/9/2023 | 7.3% | 6.5% | 71.8% |
| 11/8/2022 | -9.5% | -0.8% | 14.0% |
| 8/4/2022 | -5.5% | -12.6% | -15.5% |
| 5/4/2022 | -18.1% | -36.6% | -35.6% |
| 3/8/2022 | 7.2% | 8.0% | 14.8% |
| 11/3/2021 | 7.7% | 5.0% | -9.1% |
| 8/5/2021 | -2.0% | 1.2% | 2.3% |
| 5/6/2021 | 8.2% | 2.4% | 5.0% |
| 3/10/2021 | 14.7% | 53.6% | 44.0% |
| 11/5/2020 | 1.1% | 5.9% | 5.9% |
| 8/5/2020 | 8.2% | 15.1% | 0.6% |
| SUMMARY STATS | |||
| # Positive | 12 | 15 | 13 |
| # Negative | 13 | 10 | 12 |
| Median Positive | 7.9% | 5.9% | 14.0% |
| Median Negative | -7.3% | -12.1% | -15.2% |
| Max Positive | 14.7% | 53.6% | 88.8% |
| Max Negative | -20.9% | -36.6% | -39.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/13/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/14/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/07/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 04/26/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/13/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/14/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/07/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 04/26/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 03/11/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 03/12/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/10/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 03/16/2020 | 10-K |
| 09/30/2019 | 11/08/2019 | 10-Q |
| 06/30/2019 | 08/08/2019 | 10-Q |
Recent Forward Guidance
Updated 6/1/2026Latest: Q1 2026 Earnings Reported 5/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Revenue | 20.50 Mil | 21.50 Mil | 22.50 Mil | 2.4% | Raised | Guidance: 21.00 Mil for Q1 2026 | |
| Q2 2026 Adjusted Gross Margin | 57.0% | 58.0% | 59.0% | 0 | 0 | Affirmed | Guidance: 58.0% for Q1 2026 |
| Q2 2026 Adjusted EBITDA | 1.00 Mil | 1.50 Mil | 2.00 Mil | -6.2% | Lowered | Guidance: 1.60 Mil for Q1 2026 | |
| 2026 Revenue Growth | 2.0% | 3.0% | 4.0% | 0 | 0 | Affirmed | Guidance: 3.0% for 2026 |
| 2026 Adjusted Gross Margin | 58.0% | 59.0% | 60.0% | 0 | 0 | Affirmed | Guidance: 59.0% for 2026 |
| 2026 Adjusted EBITDA Growth | 6.0% | 8.0% | 10.0% | 0 | 0 | Affirmed | Guidance: 8.0% for 2026 |
Prior: Q4 2025 Earnings Reported 3/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | 20.00 Mil | 21.00 Mil | 22.00 Mil | ||||
| Q1 2026 Adjusted Gross Margin | 57.0% | 58.0% | 59.0% | ||||
| Q1 2026 Adjusted EBITDA | 1.00 Mil | 1.60 Mil | 2.20 Mil | ||||
| 2026 Revenue Growth | 2.0% | 3.0% | 4.0% | ||||
| 2026 Adjusted Gross Margin | 58.0% | 59.0% | 60.0% | ||||
| 2026 Adjusted EBITDA Growth | 6.0% | 8.0% | 10.0% | ||||
Insider Activity
Updated 6/11/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Frost, Mark T | Chief Financial Officer | Direct | Buy | 4012026 | 5.00 | 5,000 | 25,000 | 87,500 | Form |
| 2 | Denelsky, Stephen J | Direct | Buy | 3182026 | 4.87 | 10,000 | 48,700 | 102,270 | Form | |
| 3 | Snider, William | Direct | Buy | 3182026 | 4.85 | 8,475 | 41,104 | 155,200 | Form | |
| 4 | Snider, William | Direct | Buy | 3182026 | 4.99 | 12,525 | 62,500 | 117,390 | Form | |
| 5 | Duke, John D | Chief Executive Officer | Direct | Buy | 3172026 | 5.01 | 5,000 | 25,050 | 526,050 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Frost, Mark T | Chief Financial Officer | Direct | Buy | 4012026 | 5.00 | 5,000 | 25,000 | 87,500 | Form |
| 2 | Denelsky, Stephen J | Direct | Buy | 3182026 | 4.87 | 10,000 | 48,700 | 102,270 | Form | |
| 3 | Snider, William | Direct | Buy | 3182026 | 4.85 | 8,475 | 41,104 | 155,200 | Form | |
| 4 | Snider, William | Direct | Buy | 3182026 | 4.99 | 12,525 | 62,500 | 117,390 | Form | |
| 5 | Duke, John D | Chief Executive Officer | Direct | Buy | 3172026 | 5.01 | 5,000 | 25,050 | 526,050 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.